Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT: rationale for further study on blood pressure targets of antihypertensive treatment after stroke.

DOI: http://doi.org/10.1097/HJH.0000000000000853 Journal: J Hypertens E-pub date: 1 Mar 2016 Authors: A Zanchetti, L Liu, G Mancia, G Parati, G Grassi, M Stramba-Badiale, V Silani, G Bilo, G Corrao, A Zambon, L Scotti, X Zhang, TR Guan, Y Zhang, X Zhang, E Berge, J Redon, K Narkiewicz, A Dominiczak, P Nilsson, M Viigimaa, S Laurent, E Agabiti-Rosei, Z Wu, D Zhu, JL Rodicio, LM Ruilope, N Martell-Claros, F Pinto, RE Schmieder, M Burnier, M Banach, R Cifkova, C Farsang, A Konradi, I Lazareva, Y Sirenko, M Dorobantu, A Postadzhiyan, R Accetto, B Jelakovic, D Lovic, AJ Manolis, P Stylianou, D Dicker, G Wei, C Xu, H Xie, A Coca, J O'Brien, G Ford, ESH-CHL-SHOT trial investigators

Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT: rationale for further study on blood pressure targets of antihypertensive treatment after stroke.

Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT: rationale for further study on blood pressure targets of antihypertensive treatment after stroke.

Abstract: